CATEGORY · 55 COMPANIES
Healthcare / Life Sciences AI
Clinical scribes, patient agents, decision support, and drug discovery.
#CompanyValuationARRHeadcountFresh
01IIsomorphic LabsDeepMind drug design spinoff————02EEpistemic AIEpistemic AI applies large language models and AI to biotech, pharmaceutical, and life sciences research. Founded by Stefano Pacifico, the company leverages AI to accelerate drug discovery, molecular modeling, and biomedical research workflows, addressing the post-COVID biotech funding decline.———green03LLatent Labs<cite index="53-17">Latent Labs is an AI-driven biotechnology company developing AI foundation models to make biology programmable. The company innovates on and applies generative AI technologies to enable biotechnology and pharmaceutical companies to computationally create new molecules for therapeutic, industrial, and environmental uses.</cite>——21green04RRecursionPhenomics-driven drug discovery (public)————05NNuance DAX (Microsoft)DAX Copilot clinical scribe————06OOpenEvidencePhysician decision-support engine described as 'ChatGPT for doctors,' offered free on an ad-supported model.—>$100M revenue (ad-supported)Not separately reported—07TTerray TherapeuticsAI-first small-molecule drug discovery platform using machine learning to explore chemical space faster. Founded by Stripe co-founder Patrick Collison and biotech veterans, combining generative chemistry with traditional pharmacology workflows.———green08SSuki AIVoice-first clinical scribe————09GGuidewaysGuideways applies agentic AI to automate complex regulatory work for medical device developers, particularly FDA approval processes. The platform uses a curated knowledge base of 150,000+ FDA reference documents and expert workflows to guide teams through regulatory strategy, standards research, and submission review.———green10TTempus AIGenomic and clinical AI (public)————11CCradle BioProtein engineering AI company using generative models to design improved biologics. Enables rapid design of proteins for therapeutics, diagnostics, and industrial biotech applications without extensive manual iteration.estimated $500M—80+green12IInsilico MedicineClinical-stage biotech using generative AI for end-to-end drug discovery. Proprietary Pharma.AI platform integrates LLMs, multimodal foundation model (Nach01), and Dora research assistant. First fully AI-discovered molecule in Phase 2 trials.——180+green13AAmbience HealthcareClinical scribes and coding————14CChai DiscoveryAI-native biotech company that predicts and reprograms interactions between biochemical molecules for drug discovery. Builds foundation models tuned to design novel antibodies and therapeutic molecules with improved developability properties, tackling historically hard-to-drug targets.$1.3B——green15AAbridgeClinical ambient scribe————16PPathAIComputational pathology————17HHippocratic AIPatient-facing voice agents————18KK HealthAI primary care————19OOwkinFederated medical AI————20VValence DiscoveryValence Discovery applies AI-driven generative chemistry to accelerate drug discovery for previously intractable biology targets. The platform uses few-shot learning and proprietary molecular representation techniques to enable rapid end-to-end design of novel chemical matter against complex disease targets.———green21LLila SciencesLila Sciences develops AI Science Factories—autonomous laboratories that combine artificial intelligence, software, and robotics to accelerate scientific discovery across life sciences, chemistry, and materials science. The platform enables AI agents to design and run thousands of parallel experiments, compressing workflows that traditionally take weeks into hours.$1.3 billion—~100+green22EEliseAIAI agent platform automating healthcare and housing workflows. Deploys agentic systems for insurance eligibility, claims processing, and tenant screening at scale.$2.2B——green23AArc Institute (Evo)Arc Institute is a nonprofit research organization developing Evo, a genomic foundation model family for biological sequence modeling and design. Evo 1 (7B parameters, Nov 2024) and Evo 2 (40B parameters, March 2026) enable prediction and generative design tasks across DNA, RNA, and protein modalities at single-nucleotide resolution.———green24IInsitroMachine-learning drug discovery————25DDiligent RoboticsAustin-based pioneer in socially intelligent mobile manipulation for healthcare. Moxi robot automates hospital logistics (supply/medication delivery, lab transport) with 110,000+ autonomous elevator rides, 1.25M+ total deliveries, and deployment across 25+ US hospital facilities. Acquired by Serve Robotics (Jan 2026) to expand indoor autonomy platform.—$200k–$400k per hospital/year (reported)217 (at acquisition)green26EExscientiaPioneering AI-driven drug discovery platform integrating computational design with human expertise to accelerate development of tailored therapeutics. Platform (Centaur Chemist) identifies drug targets, designs molecules, and advances candidates to clinical trials through precision medicine approach.———green27PProsciaProscia develops digital pathology software and AI-powered image analysis tools for cancer diagnosis and drug development. Its Concentriq platform integrates whole-slide imaging with machine learning for pathology labs and pharma companies.———green28LLunitLunit develops AI-powered medical imaging software for cancer screening and treatment, with a focus on breast cancer detection and lung cancer analysis. The company is publicly traded (KOSDAQ: 328130) and has raised $561M+ across multiple rounds.———green29IIambic TherapeuticsAI-driven drug discovery company with a track record of moving compounds to clinical trials rapidly. Proprietary platform has delivered molecules to clinic in under two years. Founded by medicinal chemistry researchers.estimated $600M—40+green30iiFlytek<cite index="37-24,37-25">iFlytek is a partially state-owned Chinese information technology company established in 1999. It creates voice recognition software and 10+ voice-based internet/mobile products covering education, communication, music, intelligent toys industries.</cite> The company has pivoted into large language models (iFlytek Spark/Xinghuo) and multimodal agents, with widespread deployment in healthcare diagnostics, education, and smart devices.Market cap varies; substantial public enterpriseUndisclosed; multi-billion yuan revenue at enterprise scale3,000+green31PPathos AIPathos AI develops machine learning platforms for translational and computational biology, enabling drug discovery and development at scale. The company raised $467M across three rounds, achieving the highest average per-round capital of any active private AI drug discovery company.———green32CCradleAI-powered protein engineering company using generative AI to design improved proteins and accelerate research and development. Platform enables faster, cheaper creation of bio-based products for therapeutics, diagnostics, food, chemicals, and agriculture by automating protein design workflows.———green33BBoltzPublic benefit corporation developing commercially-available co-folding AI models (Boltz-1) achieving AlphaFold 3-level accuracy in predicting 3D structures of biomolecular complexes. Enables structure-guided drug discovery by predicting protein-protein interactions, small-molecule binding, and biologics design.———green34GGenerate BiomedicinesClinical-stage biotech pioneering Generative Biology—using diffusion and graph-based AI models integrated with scalable biohardware (cell-free expression, multiplexed assays, cryo-EM core) to design protein therapeutics de novo. Platform combines design–build–test–learn loop for rapid therapeutic validation.——312 (138 PhD/MD holders)green35TTruvetaBuilds the world's largest and most diverse database of genotypic and phenotypic patient information to accelerate drug discovery and precision medicine. Aggregates real-world clinical and genomic data from healthcare providers to train AI models for patient stratification, biomarker discovery, and clinical trial recruitment.~$1B+ (estimated post-Series C)—~100-150 (estimated)green36NNectirNectir is secure AI infrastructure purpose-built for higher education institutions. The platform provides 24/7 personalized learning support grounded in course content through compliant AI systems that enhance learning outcomes while maintaining academic integrity without compromising trust or privacy.———green37BBioAge LabsAI-driven therapeutics company researching molecular pathways that contribute to aging and healthspan. Uses systems biology and machine learning trained on clinical and molecular data from thousands of patients to develop novel small-molecule therapeutics for aging-related diseases, oncology, and CNS disorders.$1B+ (post-IPO, 2025)—~150-200 (estimated)green38AAqemia<cite index="1-6,1-7">Aqemia combines generative AI with deep physics simulations to revolutionize drug discovery at the molecular level. Founded in 2019, it has raised over $100 million and, in 2025, expanded its operations to London as it moves closer to launching clinical trials for its AI-discovered drug candidates.</cite> <cite index="1-5">Reduces the energy consumption of AI training by up to 80%, enabling scalable and eco-friendly AI deployments.</cite>———green39XXaira TherapeuticsXaira Therapeutics is an AI-driven drug discovery platform using protein design diffusion models and generative chemistry to engineer novel therapeutics. Founded by Nobel laureate David Baker and computational biology experts, it raised $1B in Series A funding—one of the largest healthcare venture rounds ever.———green40AAnima BiotechAI drug discovery platform using its proprietary mRNA Lightning.AI platform to image hundreds of cellular pathways in healthy and diseased cells, training disease-specific AI models to identify dysregulated pathways and uncover novel drug targets. Combines functional genomics with deep learning for target validation.———green41CConverge BioGenerative AI platform accelerating drug discovery and development by automating target identification, antibody design, and protein optimization. Works across oncology, autoimmune, and neurodegenerative research.——34 employeesgreen42BBioptimusBioptimus builds universal foundation AI models for biology, integrating data across molecular to organismal scales to accelerate drug discovery and precision medicine. The company released H-Optimus-0, a foundational model for pathology trained on over 500,000 histopathology slides, with plans to launch M-Optimus, a multi-scale, multi-modal model simulating complex biological processes.undisclosed (Series A+ 2024)—undisclosedgreen43FFreenomeFreenome develops AI-powered blood tests for early cancer detection through machine learning analysis of circulating tumor DNA and proteins. The company has raised $1.4B cumulatively, targeting cancer diagnostics at the earliest disease stages.———green44OOrrecoAgentic AI platform combining applied physiology, biostatistics, and cognitive computing to optimize athlete performance and reduce injury risk. Provides biomarker surveillance, training load analysis, motion signal detection, and women's performance modules powered by proprietary Bayesian models.undisclosedundisclosed~80+ (expanding to 110+)green45NNoetikAI company building biological foundation models trained on human tissue data for translational research. Generates multimodal data from primary human tissue samples and trains models to predict clinical outcomes in cancer and other diseases, bridging the gap between molecular data and human efficacy.~$400-600M (estimated)—~60-80 (estimated)green46FFormation BioFormation Bio uses AI to accelerate drug development timelines and de-risk clinical programs through predictive modeling and patient selection. The company raised $372M in a Series D round led by Andreessen Horowitz in 2024.———green47VVuMediVuMedi is a video-sharing platform for clinicians and surgeons featuring AI-powered content recommendation, categorization, and curation. The platform provides 100,000+ educational videos and leverages AI to surface relevant medical content based on specialty, skill level, and clinical trends for personalized continuing education.——200-500green48ZZone7AI-powered injury prediction and prevention platform for professional sports teams. Uses machine learning to forecast soft-tissue injury risk by analyzing player workload data, movement patterns, and physiological metrics. Integrates with GPS trackers and wearables.undisclosedundisclosed~40green49EEvolutionaryScale (ESM3)EvolutionaryScale is a frontier AI research lab for biology, founded by members of the team that built Meta's ESM protein language models. Its flagship model ESM3 is a generative model that reasons jointly over protein sequence, structure, and function to design novel proteins.———green50SSuperDialSuperDial builds voice AI agents to automate high-friction phone calls in healthcare billing and provider operations. The company emerged from SuperBill, a revenue cycle management startup, and replaces hours of manual insurer calls with end-to-end AI agents. SuperDial navigates phone trees, processes holds, and conducts complex negotiations between providers and insurance companies.———green51VVinBrain<cite index="30-3,30-4">VinBrain is an AI healthcare startup funded by Vingroup that develops AI-based medical devices and software for diagnostics</cite>. <cite index="30-5,30-6">VinBrain's AI tools have been deployed in 182+ hospitals across Vietnam and abroad for analysis of X-rays, lab tests and pathology images</cite>.———green52CCytoReasonAI-powered computational disease modeling platform for pharmaceutical and biotech companies. Uses machine learning to map human diseases and predict drug efficacy, helping accelerate clinical trials and reduce development costs.——120+green53AAMBOSSAMBOSS is a digital medical knowledge platform providing clinical decision support and medical education tools for medical students and healthcare professionals. The platform combines peer-reviewed medical content with AI-powered features including semantic search, study recommendations, and clinical intelligence (LiSA) ranked #1 in Stanford-Harvard NOHARM safety studies.$undisclosed (likely $1B+)~$80-100M estimated500+green54CCommureCommure builds an AI-powered operating system for healthcare providers, spanning ambient clinical documentation, revenue cycle management (RCM), and practice operations. It runs across hundreds of health systems and integrates with dozens of electronic health record (EHR) systems.$7B——green55TTennrTennr automates the patient referral process for healthcare providers, using an orchestration engine paired with specialized language models (RaeLM) to parse faxed and scanned medical documents against payer criteria. Its Tennr Network adds a coordination layer for referral status visibility.$605Meight-figure revenue (reported)—green